The goal of this first-in-human clinical trial is to examine the safety and efficacy of treatment with a new peritoneal dialysis (PD) device called WEAKID (WEarable Artificial KIDney for peritoneal dialysis). This device, unlike conventional PD, allows for continuous flow of dialysate inside the abdominal cavity combined with continuous regeneration of spent dialysate thanks to sorbents that remove toxins from the fluid. The study will include PD patients of 18 years or older with a well-functioning peritoneal catheter and no history of a PD-related infection for at least eight weeks prior to enrolment. The main purpose of this study is to assess the (short-term) safety of the WEAKID system in a limited number (n=12) of patients and sessions. Participants will undergo six treatment sessions (of four or eight hours) in total over a period of two weeks, either with or without a sorbent chamber. Participants will be asked to collect urine and dialysate the week before the first treatment and during the treatment days. In addition, blood samples will be collected before and during the treatment weeks in order to compare the effects of conventional PD with that of WEAKID treatment. A peritoneal equilibrium test will also be done before and after the treatment weeks to test the function of the lining of the abdomen (the peritoneal membrane).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Serious adverse device effects (SADEs) and device deficiencies (DDs)
Timeframe: This will be assessed through study completion (four weeks in total per participant)
Critical changes in blood pressure
Timeframe: This will be assessed during WEAKID treatment throughout the study treatment period (2 weeks in total per participant)
Critical changes in heart rate
Timeframe: This will be assessed during WEAKID treatment throughout the study treatment period (2 weeks in total per participant)
Critical changes in body temperature
Timeframe: This will be assessed during WEAKID treatment throughout the study treatment period (2 weeks in total per participant)
Critical changes in oxygen saturation
Timeframe: This will be assessed during WEAKID treatment throughout the study treatment period (2 weeks in total per participant)
Critical changes in plasma potassium
Timeframe: This will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)
Critical changes in plasma calcium
Timeframe: This will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)
Critical changes in plasma bicarbonate
Timeframe: This will be assessed before (at t=0 minutes) and after (at t=240 minutes or t=480 minutes for the 4-hour and 8-hour treatment, respectively) the WEAKID treatment throughout the study treatment period (2 weeks in total per participant)
Critical changes in intra-abdominal dialysate volume
Timeframe: This will be assessed during WEAKID treatment throughout the study treatment period (2 weeks in total per participant)
Critical changes in intra-abdominal pressure
Timeframe: This will be assessed during WEAKID treatment throughout the study treatment period (2 weeks in total per participant)